Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2023

Segment Reporting [Abstract]

Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]

A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying unaudited consolidated statements of operations is as follows (in millions, except percentages).

	Three Months Ended March 31,
Net Sales	2023		2022
MedSurg	$	1,252	$	1,164
Cardiovascular	2,049		1,902
Total net sales of reportable segments	3,301		3,066
Impact of foreign currency fluctuations	88		(40)
	$	3,389	$	3,026

Income (loss) before income taxes
MedSurg	$	400	$	371
Cardiovascular	541		477
Total operating income of reportable segments	940		847
Unallocated amounts:
Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments	(75)		(66)
Goodwill and intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs	(110)		(117)
Amortization expense	(203)		(198)
Operating income (loss)	552		466
Other expense, net	(108)		(310)
Income (loss) before income taxes	$	444	$	156

	Three Months Ended March 31,
Operating income margin of reportable segments	2023		2022
MedSurg	31.9	%	31.8	%
Cardiovascular	26.4	%	25.1	%